 |
4 Products |  |
0 Diseases | | 4 Products |
|
10 Trials |  |
33 News |  |
- GD2-targeted CAR-T cells / Sinobioway
GD2-targeted CAR T cell therapy for childhood solid tumours (RTM Stage) - May 11, 2024 - Abstract #EACR2024EACR_142;
- GD2-targeted CAR-T cells / Sinobioway
Priming of the glioblastoma tumour microenvironment via copper chelation to enhance the efficacy of immunotherapies (Section 5) - Mar 5, 2024 - Abstract #AACR2024AACR_4182;
In an immunocompetent murine glioblastoma model, combination therapy with GD2-targeted CAR-T cells and TETA effectively slowed tumor growth, demonstrating enhanced efficacy...Our findings suggest that copper chelation, with agents like TETA, can be repurposed as a viable anticancer therapy when combined with immunotherapies. This study provides a compelling rationale for further pre-clinical validation, offering a potential breakthrough in the quest for effective glioblastoma treatments.
- || CD19-targeted CAR-T cells / Sinobioway
Enrollment closed, Enrollment change, Trial completion date: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Jul 15, 2020
P=N/A, N=72, Active, not recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
This study provides a compelling rationale for further pre-clinical validation, offering a potential breakthrough in the quest for effective glioblastoma treatments. Recruiting --> Active, not recruiting | N=24 --> 72 | Trial completion date: Nov 2019 --> Dec 2025
- AUTO6NG / Autolus
AUTO6NG overcomes immune suppressive mechanisms in the TME and demonstrate preclinical anti-tumor activity in GD2-expressing solid tumors (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1650;
These CAR-T cells also demonstrated enhanced tumor infiltration and anti-tumor activity in vivo in xenografts mouse models. Our findings suggest that GD2 targeted CAR-T cell therapy is a viable novel approach for the treatment of multiple solid tumors indications.
- GD2-targeted CAR-T cells / Sinobioway
AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFβ and checkpoint inhibition for relapsed/refractory neuroblastoma (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_510;
P1
These results demonstrate the feasibility, safety, and efficacy of AUTO6NG T-cells. The addition of IL7R_CCR, dnTGFβRII and dSHP2 modules to the AUTO6NG product augment its functions by extending T-cell persistence and rendering modified T-cells resistant to TGFβ- and PD1/PDL1-driven immune inhibition.
- | GD2-targeted CAR-T cells / Sinobioway
Clinical, Journal, CAR T-Cell Therapy: Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M diffuse midline gliomas. (Pubmed Central) - May 22, 2019
Given the precarious neuroanatomical location of midline gliomas, careful monitoring and aggressive neurointensive care management will be required for human translation. With a cautious multidisciplinary clinical approach, GD2-targeted CAR T cell therapy for H3-K27M diffuse gliomas of pons, thalamus and spinal cord could prove transformative for these lethal childhood cancers.
- CD19-targeted CAR-T cells / Sinobioway
New trial, CAR T-Cell Therapy: CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma (clinicaltrials.gov) - Apr 3, 2018
P=N/A, N=6, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- CD19-targeted CAR-T cells / Sinobioway
Enrollment open: EECBL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
With a cautious multidisciplinary clinical approach, GD2-targeted CAR T cell therapy for H3-K27M diffuse gliomas of pons, thalamus and spinal cord could prove transformative for these lethal childhood cancers. Suspended --> Recruiting
- EPCAM-targeted CAR-T cells / Sinobioway
Enrollment open: Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=19, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Suspended --> Recruiting Suspended --> Recruiting
- EPCAM-targeted CAR-T cells / Sinobioway
Phase classification, Trial primary completion date: EECLC: Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=25, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Suspended --> Recruiting Phase classification: P1/2 --> P=N/A | Trial primary completion date: Oct 2016 --> Nov 2019
- EPCAM-targeted CAR-T cells / Sinobioway
Phase classification, Trial suspension, Trial primary completion date: Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (clinicaltrials.gov) - Mar 14, 2017
P=N/A, N=19, Suspended, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Phase classification: P1/2 --> P=N/A | Trial primary completion date: Oct 2016 --> Nov 2019 Phase classification: P1/2 --> P=N/A | Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Nov 2019
- GD2-targeted CAR-T cells / Sinobioway
Phase classification, CAR T-Cell Therapy: Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=22, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Phase classification: P1/2 --> P=N/A | Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Nov 2019 Phase classification: P1/2 --> P=N/A
- CD19-targeted CAR-T cells / Sinobioway
Phase classification, Trial primary completion date: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Phase classification: P1/2 --> P=N/A Phase classification: P1/2 --> P=N/A | Trial primary completion date: May 2019 --> Nov 2019
- CD19-targeted CAR-T cells / Sinobioway
Phase classification, Trial initiation date, Trial suspension, Trial primary completion date: EECBL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=24, Suspended, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Phase classification: P1/2 --> P=N/A | Trial primary completion date: May 2019 --> Nov 2019 Phase classification: P1/2 --> P=N/A | Initiation date: Nov 2015 --> Jul 2015 | Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2019
- CD19-targeted CAR-T cells / Sinobioway
Trial primary completion date: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Nov 22, 2016
P1/2, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
Phase classification: P1/2 --> P=N/A | Initiation date: Nov 2015 --> Jul 2015 | Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2019 Trial primary completion date: Oct 2016 --> May 2019
- | GD2-targeted CAR-T cells / Sinobioway
New P1/2 trial, CAR T-Cell Therapy: Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children (clinicaltrials.gov) - Sep 29, 2016
P1/2, N=22, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- CD19-targeted CAR-T cells / Sinobioway
New P1/2 trial: EECNTL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (clinicaltrials.gov) - Apr 12, 2016
P1/2, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- CD19-targeted CAR-T cells / Sinobioway
New P1/2 trial: EECBL: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=24, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- EPCAM-targeted CAR-T cells / Sinobioway
New P1/2 trial: EECLC: Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=25, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- EPCAM-targeted CAR-T cells / Sinobioway
New P1/2 trial: Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (clinicaltrials.gov) - Mar 31, 2016
P1/2, N=19, Recruiting, Sponsor: Sinobioway Cell Therapy Co., Ltd.
- Stem cell educator therapy / Sinobioway
Enrollment change: Stem Cell Educator Therapy in Type 2 Diabetes (clinicaltrials.gov) - Feb 15, 2012
P1/2, N=25, Completed, Sponsor: University of Illinois at Chicago
Trial primary completion date: Oct 2016 --> May 2019 N=100 --> 25
- Stem cell educator therapy / Sinobioway
Trial completion: Stem Cell Educator Therapy in Type 2 Diabetes (clinicaltrials.gov) - Feb 15, 2012
P1/2, N=25, Completed, Sponsor: University of Illinois at Chicago
N=100 --> 25 Recruiting --> Completed
- Stem cell educator therapy / Sinobioway
New P1/2 trial: Stem Cell Educator Therapy in Type 2 Diabetes (clinicaltrials.gov) - Aug 9, 2011
P1/2, N=25, Completed, Sponsor: University of Illinois at Chicago